company background image
ATX

Amplia Therapeutics ASX:ATX Stock Report

Last Price

AU$0.086

Market Cap

AU$16.7m

7D

1.2%

1Y

-47.9%

Updated

04 Feb, 2023

Data

Company Financials

ATX Stock Overview

Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia.

ATX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

New

Notes are coming soon

Amplia Therapeutics Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Amplia Therapeutics
Historical stock prices
Current Share PriceAU$0.086
52 Week HighAU$0.18
52 Week LowAU$0.08
Beta0.37
1 Month Change4.88%
3 Month Change-13.13%
1 Year Change-47.88%
3 Year Change21.13%
5 Year Change-71.33%
Change since IPO-95.70%

Recent News & Updates

Recent updates

We Think Amplia Therapeutics (ASX:ATX) Needs To Drive Business Growth Carefully

Jan 13
We Think Amplia Therapeutics (ASX:ATX) Needs To Drive Business Growth Carefully

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Apr 28
Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Amplia Therapeutics Limited (ASX:ATX) Insiders Increased Their Holdings

Feb 28
Amplia Therapeutics Limited (ASX:ATX) Insiders Increased Their Holdings

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Jan 06
Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Shareholder Returns

ATXAU BiotechsAU Market
7D1.2%6.0%0.8%
1Y-47.9%17.9%2.2%

Return vs Industry: ATX underperformed the Australian Biotechs industry which returned 17.9% over the past year.

Return vs Market: ATX underperformed the Australian Market which returned 2.2% over the past year.

Price Volatility

Is ATX's price volatile compared to industry and market?
ATX volatility
ATX Average Weekly Movement6.9%
Biotechs Industry Average Movement8.9%
Market Average Movement8.5%
10% most volatile stocks in AU Market15.5%
10% least volatile stocks in AU Market3.4%

Stable Share Price: ATX is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: ATX's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2000n/aChris Burnshttps://www.ampliatx.com

Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The company’s product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for cancer and fibrotic disease indication. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney.

Amplia Therapeutics Limited Fundamentals Summary

How do Amplia Therapeutics's earnings and revenue compare to its market cap?
ATX fundamental statistics
Market CapAU$16.68m
Earnings (TTM)-AU$5.23m
Revenue (TTM)AU$2.99m

5.6x

P/S Ratio

-3.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ATX income statement (TTM)
RevenueAU$2.99m
Cost of RevenueAU$182.52k
Gross ProfitAU$2.81m
Other ExpensesAU$8.04m
Earnings-AU$5.23m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.027
Gross Margin93.90%
Net Profit Margin-175.02%
Debt/Equity Ratio11.1%

How did ATX perform over the long term?

See historical performance and comparison